摘要
目的研究冻干重组人脑利钠肽治疗充血性心力衰竭的疗效。方法 90例充血性心力衰竭患者,随机分为对照组和观察组。对照组采用米力农治疗,观察组采用冻干重组人脑利钠肽治疗。结果观察组总有效率97.78%高于对照组的82.22%,差异有统计学意义(P<0.05)。观察组步行运动耐量(304.6±40.5)m优于对照组的(213.5±36.6)m,差异有高度统计学意义(P<0.01)。结论冻干重组人脑利钠肽治疗充血性心力衰竭短期疗效显著,安全性高。
Objective To study of lyophilized recombinant human brain natriuretic peptide treatment of congestive heart failure. Methods All 90 patients with congestive heart failure patients were randomly divided into the control group and the observation group. The control group used Milrinone treatment,the observation group was treated with lyophilized re- combinant human brain natriuretic peptide. Results The total efficiency of the observation group was 97.78% higher than 82.22% in the control group,the difference was statistically significant（P 〈 0.05）. Walking exercise tolerance of the obser- vation group （304.6±40.5） m was better than that of the control group （213.5±36.6） m, the difference was statistically sig- nificant （P 〈 0.01 ）. Conclusion Lyophilized recombinant human brain natriuretic peptide treatment of patients with congestive heart failure of short-term curative effect, high safety.
出处
《中国现代医生》
2012年第21期56-57,共2页
China Modern Doctor
关键词
冻干重组人脑利钠肽
充血性心力衰竭
米力农
利尿剂
Lyophilized recombinant human brain natriuretic peptide
Congestive heart failure
Milrinone
Diuretic
